

# Contents

<b>1</b>	<b>Melanoma: Historical Context.....</b>	<b>1</b>
	Suraj Venna, Sekwon Jang and Michael Atkins	
<b>2</b>	<b>Melanoma Pathogenesis .....</b>	<b>25</b>
	Jennifer A. Lo and David E. Fisher	
<b>3</b>	<b>Molecular Diagnostics and Tumor Mutational Analysis .....</b>	<b>47</b>
	Melissa A. Wilson and Katherine L. Nathanson	
<b>4</b>	<b>Clinical Utility of BRAF-Targeted Therapy in Melanoma .....</b>	<b>67</b>
	Jeffrey A. Sosman and Douglas B. Johnson	
<b>5</b>	<b>The Ethics of Randomized Trials in Oncology .....</b>	<b>85</b>
	Pallavi Kumar and Ryan J. Sullivan	
<b>6</b>	<b>Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma .....</b>	<b>105</b>
	Michael A. Davies	
<b>7</b>	<b>Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy .....</b>	<b>137</b>
	Dale Han and Keiran SM Smalley	
<b>8</b>	<b>Combination BRAF-Directed Therapy and Immunotherapy .....</b>	<b>163</b>
	Zachary A. Cooper, Zain Ahmed and Jennifer A. Wargo	
<b>9</b>	<b>Moving Forward: Making BRAF-Targeted Therapy Better .....</b>	<b>183</b>
	Keith T. Flaherty	
	<b>Index.....</b>	<b>203</b>